Latest in Cardiology from ACC.org

• IRIS-MAIN: No Statistical Difference in Mortality Between PCI and CABG in Asian Patients With Left Main CAD
  No statistically significant difference in long-term all-cause mortality was observed among Asian patients with unprotected left main coronary artery disease (CAD) who underwent PCI or CABG, based on a non-randomized analysis of the IRIS-MAIN registry presented at TCT 2026 and simultaneously published in The Lancet.
• SINGLE-CLOSURE: Single-ProGlide Strategy Noninferior to Double-ProGlide For Post-TAVR Access Site Closure
  A single-ProGlide strategy may be noninferior for a composite of access-site or access-related vascular complications compared to conventional double-ProGlide closure following transfemoral TAVR, according to results of the SINGLE-CLOSURE trial presented at TCT 2026 and simultaneously published in JACC.
• SPYRAL AFFIRM: Radiofrequency RDN Effective on BP at Six Months
  Radiofrequency renal denervation (RDN) utilizing the Symplicity Spyral device may effectively lower in-office systolic blood pressure (BP) at six months, according to results from the SPYRAL AFFIRM study presented at TCT 2026 and simultaneously published in Circulation: Cardiovascular Interventions.
• PIONEER IV: Angiography-Derived FFR vs. Usual Care in Patients Undergoing PCI
  Noninferiority of angiography-derived fractional flow reserve (angio-FFR) was not met when compared to usual care in patients undergoing PCI, according to results of the PIONEER IV trial, presented at TCT 2026.
• A-CLOSE: Clopidogrel or Extended DAPT in High Ischemic Risk?
  The A-CLOSE (A Randomized Comparison of CLOpidogrel Monotherapy Versus Extended Dual-antiplatelet Therapy Beyond 12 Months After Implantation of Drug-eluting StEnts in High-risk Lesions or Patients) trial compared clopidogrel monotherapy with extended dual antiplatelet therapy (DAPT) with clopidogrel plus aspirin...